FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Is Shire worth a 25% premium?

Can Shire weather the upcoming loss of Adderall XR to the off-patent wildnerness? Company execs say it can: They point out that 60 percent of the company's revenues derive from other products. And they say Vyvase, their new ADHD med, will pick up the Adderall slack--despite the fact that its uptake so far hasn't met expectations. But as Barron's points out, Shire is trading now at 15 times earnings, a 25 percent premium to the current industry multiple of 12 times. If the FDA doesn't listen to Shire's petition--which calls for XR copycats to undergo clinical trials--then generics will hit the market next year. And if Vyvanse doesn't step up to the plate, "Shire wouldn't merit its 25 percent premium," Barron's bluntly states. That's a lot of "ifs"--on either side.

- see the Barron's analysis

Related Articles:
What's Shire doing to support Vyvanse?
Shire gambit aimed at delaying generic Adderall XR
Shire on lookout for acquisitions

More stories about Shire   Vyvanse   Adderall   generic competition  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 58 + 35?
To combat spam, please solve the math question above.